Related Experiment Video
Updated: Aug 18, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
How to accelerate the endothelialization of stents
A T L Ong1, J Aoki, M J Kutryk
1Erasmus MC Thoraxcenter, Rotterdam, The Netherlands.
Insights
Accelerating endothelial repair after coronary stenting is key for healing. Strategies focus on enhancing endothelial progenitor cells (EPCs) recruitment to reduce complications like neointimal hyperplasia and stent thrombosis.
Area of Science:
- Cardiovascular Biology
- Biomedical Engineering
- Regenerative Medicine
Background:
- Coronary artery stenting, a common treatment for coronary artery disease, injures the vascular endothelium.
- Endothelial injury triggers inflammation, repair processes, and neointimal hyperplasia.
- Endothelial repair relies on endothelial cell migration and circulating endothelial progenitor cells (EPCs).
Purpose of the Study:
- To explore methods for accelerating reendothelialization after coronary stenting.
- To investigate therapeutic approaches that enhance endothelial repair and reduce adverse outcomes.
- To review current strategies for augmenting endothelial progenitor cell (EPC) recruitment and function.
Main Methods:
- Review of studies on agents promoting EPC mobilization and recruitment (e.g., statins, exercise, estrogen, cytokines).
- Examination of stent-based strategies, including endothelial cell or EPC seeding.
- Analysis of advanced techniques like coating stents with anti-CD34 antibodies to attract circulating EPCs.
Main Results:
- Current drug-eluting stents can interfere with natural endothelial repair mechanisms.
- Accelerated reendothelialization offers potential benefits in reducing neointimal hyperplasia and stent thrombosis.
- Emerging strategies focus on leveraging EPCs for enhanced vascular healing post-stenting.
Conclusions:
- Enhancing endothelial repair following stenting is a promising therapeutic avenue.
- Targeting endothelial progenitor cells (EPCs) represents a key strategy for improving stent outcomes.
- Anti-CD34 antibody-coated stents are under investigation for their potential to promote EPC-mediated reendothelialization.
Abstract:
Coronary artery stenting is currently the most frequently performed percutaneous coronary intervention for the treatment of coronary artery disease. The endothelium is a single layer of endothelial cells lining the vascular wall and plays an integral part in maintaining vascular homeostasis. Stenting however causes significant injury to the vascular wall and endothelium, resulting in inflammation, repair and the development of neointimal hyperplasia. The ability of the endothelium to repair itself depends on both the migration of surrounding mature endothelial cells, and the attraction and adhesion of circulating endothelial progenitor cells (EPCs) to the injured region, which then differentiate into endothelial-like cells. Current therapies with drug-eluting stents interrupt the natural response to damage. Accelerating the reendothelialization of the damaged arterial segment following stent implantation is an attractive form of therapy as it is seen as hastening the natural process of repair. It potentially has the benefit of reducing the amount of neointimal hyperplasia and stent thrombosis. Studies have been performed to identify agents that augment the mobilisation and recruitment of EPCs to the injured area (statins, exercise, estrogen and cytokines). Other studies have looked at seeding stents with endothelial cells or EPCs. The most current approach is to coat anti-CD34 antibodies on a stent surface to attract circulating EPCs to the stent which then differentiate into endothelial-like cells. This approach is currently being tested in safety and feasibility clinical studies.
